Caprolisin Injection

Caprolisin Injection is used for: Haemorrhage, Missed abortion, Hereditary hemorrhagic telangiectasia,Traumatic hyphema, Dental bleeding, Hemophilia A, Postoperative bleeding, Systemic hyperfibrinolysis

Intravenous Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g as a 2% solution over 1 hr followed by a 1 g/hr infusion continued for up to 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Oral Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g, followed by 1-1.25 g every hr for about 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Patients with haemophilia undergoing dental extraction Adult: Initially, 6 g immediately after the procedure, followed by 6 g every 6 hr for up to 10 days.

Renal impairment: Dosage reduction may be required.

IV Administration Initial 5 g in 250 mL over 1 hr, each subsequent gram in 50-100 mL at 1 g/hr Rapid injection undiluted into a vein is not recommended Continue for about 8 hr or until bleeding has been controlled Oral May be taken with or without food. May be taken w/ meals to prevent GI upset.

Bleeding due to disseminated intravascular coagulation. Rapid IV administration. Evidence of active intravascular clotting process

Use cautioni in renal/cardiac/hepatic impairment In patients with upper urinary tract bleeding, therapy has been known to cause intrarenal obstruction in form of glomerular capillary thrombosis or clots in renal pelvis and ureters; for this reason, drug should not be used in hematuria of upper urinary tract origin, unless possible benefits outweigh risks Avoid rapid IV administration Therapy inhibits both action of plasminogen activators and to a lesser degree, plasmin activity; drug should not be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia) Preservative benzyl alcohol linked to fatal "Gasping Syndrome" in premature neonates Skeletal muscle weakness with necrosis of muscle fibers reported following prolonged administration (rare); Clinical presentation may range from mild myalgias with weakness and fatigue to severe proximal myopathy with rhabdomyolysis, myoglobinuria, and acute renal failure; muscle enzymes, especially creatine phosphokinase (CPK) are elevated; monitor CPK levels in patients on long-term therapy; stop therapy if rise in CPK noted; resolution follows discontinuation of therapy; however, syndrome may recur if therapy restarted Inhibition of fibrinolysis may theoretically result in clotting or thrombosis; there is no definite evidence that therapy has been responsible for few reported cases of intravascular clotting which followed treatment; rather, it appears that intravascular clotting was most likely due to patient's preexisting clinical condition, eg, the presence of DIC; it has been postulated that extravascular clots formed in vivo may not undergo spontaneous Iysis as do normal clots Therapy should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as risk of thrombosis may increase Reports have appeared in literature of increased incidence of certain neurological deficits,j including hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with use of antifibrinolytic agents in treatment of subarachnoid hemorrhage (SAH); all of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography; drug relatedness remains unclear

Pregnancy Category: C Lactation: Not known whether excreted in breast milk, use caution

Increased risk of hypercoagulability with OC and oestrogens.

Side effects of Aminocaproic Acid : Frequency Not Defined Confusion Vision decrease Vomiting Headache Convulsions Malaise Muscle weakness Dizziness Tinnitus Nausea Bradycardia Thrombosis Edema Hypotension Stroke Syncope Intracranial hypertension Peripheral ischemia Pulmonary embolism Dyspnea Congestion Diarrhea Abdominal pain Leukopenia Agranulocytosis Coagulation disorder Dry ejaculation Injection site reactions (pain/necrosis) Myopathy Pruritus Rash Renal failure Anaphylaxis Potentially Fatal: Cardiac and hepatic damage.

Aminocaproic acid inhibits the action of plasminogen activators and, to a lesser extent, it also has some antiplasmin activity.

Caprolisin Injection manufactured by Pacific Pharmaceuticals Ltd.. Its generic name is Aminocaproic Acid. Caprolisin is availble in Bangladesh. Farmaco BD drug index information on Caprolisin Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.